Please wait while the transcript is being prepared...
0:00
Hello everyone. Thanks for
joining Part 1 of my talk.
Today we will be looking
at the development of
monoclonal antibodies or mAbs in
short and several
antibody-based products.
My name is Veysel Kayser.
I work at the
University of Sydney as
an associate professor in
the School of Pharmacy.
There are many different terms
in the literature for biologics,
such as biotherapeutics,
biologic molecules,
biomedicine, etc.
Although these terms refer to
slightly different
things depending
on the context, in this lecture
I'll use them interchangeably.
0:35
Outline of the lecture
is listed in this slide.
First, we will learn
about various terms
and phrases and talk about
why they are important.
Then we will compare
biologics with
small molecules and
discuss their attributes.
Then talk about mAbs,
different types of
antibody-based biologics
and new developments including
antibody-drug
conjugates or ADCs by
specifics and immune
checkpoint inhibitors.
1:04
Biologics are quite
different from
small molecules and they cannot
be synthesized by
chemical synthesis.
So active substance, which is
mostly a protein
such as an antibody,
is produced or derived from
a living organisms
or in cell culture.
In the case of antibodies,
mammalian cell
culture for instance,
chore or excels are used.
They have different sizes,
for example many
hormones and peptides
such as insulin are
small biologics,
but some biologics
are large proteins,
for example monoclonal
antibodies,
or even cells like T-cells.
Most biologics are
proteins and they are
produced recombinantly in
mammalian cell culture.
